Charles Meng - SciClone Pharmaceuticals VP of Compliance and General Counsel

VP

Mr. Charles Meng is the Vice President Compliance General Counsel of Sciclone Pharmaceuticals Inc. Mr. Meng joined SciClone in February 2014 and serves as General Counsel and Vice President of Compliance. Prior to joining SciClone from 2012 to 2014 Mr. Meng served as General Legal Counsel and Chief Compliance Officer at Novartis China a health care products company. Prior to Novartis from June 2011 to December 2011 Mr. Meng served as Chief Legal Officer of China National Bluestar Co. Ltd. in Beijing a stateowned chemical company. From 2006 to 2011 Mr. Meng held the position of Legal Director Greater China Region with AMD Ltd since 2014.
Age 51
Tenure 10 years
Phone650 358-3456
Webwww.sciclone.com
Meng earned his LL.B. from Foreign Affairs College in Beijing, his LL.M from the Faculty of Law, Edinburgh University, Scotland, UK, and his J.D. from the College of Law, Ohio State University.

SciClone Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, offer therapies for oncology, infectious diseases, and cardiovascular disorders in the People?s Republic of China, the United States, and Hong Kong. SciClone Pharmaceuticals (SCLN) is traded on NASDAQ Exchange in USA and employs 590 people.

Management Performance

SciClone Pharmaceuticals Leadership Team

Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Meng, VP of Compliance and General Counsel
Richard Hawkins, Independent Director
Gregg Lapointe, Independent Director
Hong Zhao, CEO of China Operations
Wilson Cheung, CFO, Sr. VP of Fin. and Secretary
Nancy Chang, Director
Anthony Lapointe, Independent Director
Lan Xie, VP of Fin. and CFO of China Operations
Raymond Low, Vice President - Finance, Controller
Robert King, Senior Vice President - Product Development and Supply Chain
Simon Li, Independent Director
Jon Saxe, Independent Chairman of the Board
Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee

SciClone Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards SciClone Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, SciClone Pharmaceuticals' short interest history, or implied volatility extrapolated from SciClone Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Consideration for investing in SciClone Stock

If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum